Numab Therapeutics is an oncology-focused biopharmaceutical company based in the Zurich-area, Switzerland. At Numab, we are writing the next chapter in cancer immunotherapy by creating multi-specific antibodies that enable the pursuit of novel therapeutic strategies. With our proprietary MATCH™ technology platform we are fueling a new wave of multi-specific drug candidates engineered with versatility and developability in mind. Our lead product was designed to balance potent anti-tumor immunity with a desirable safety profile by targeting 4-1BB, PD-L1 and Human Serum Albumin simultaneously. We believe meeting the highest quality standards in every step of the drug design process matters and will result in better patient outcomes.